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Abstract
Background: Regulator of G protein signaling (RGS) proteins suppress G protein coupled receptor signaling by
catalyzing the hydrolysis of Gα-bound guanine nucleotide triphosphate. Transgenic mice in which RGS-mediated
regulation of Gαi2 is lost (RGS insensitive Gαi2G184S) exhibit beneficial (protection against ischemic injury) and detrimental
(enhanced fibrosis) cardiac phenotypes. This mouse model has revealed the physiological significance of RGS/Gαi2
interactions. Previous studies of the Gαi2G184S mutation used mice that express this mutant protein throughout their
lives. Thus, it is unclear whether these phenotypes result from chronic or acute Gαi2G184S expression. We addressed this
issue by developing mice that conditionally express Gαi2G184S.
Methods: Mice that conditionally express RGS insensitive Gαi2G184S were generated using a floxed minigene strategy.
Conditional expression of Gαi2G184S was characterized by reverse transcription polymerase chain reaction and by
enhancement of agonist-induced inhibition of cAMP production in isolated cardiac fibroblasts. The impact of
conditional RGS insensitive Gαi2G184S expression on ischemic injury was assessed by measuring contractile recovery
and infarct sizes in isolated hearts subjected to 30 min ischemia and 2 hours reperfusion.
Results: We demonstrate tamoxifen-dependent expression of Gαi2G184S, enhanced inhibition of cAMP production, and
cardioprotection from ischemic injury in hearts conditionally expressing Gαi2G184S. Thus the cardioprotective phenotype
previously reported in mice expressing Gαi2G184S does not require embryonic or chronic Gαi2G184S expression. Rather,
cardioprotection occurs following acute (days rather than months) expression of Gαi2G184S.
Conclusions: These data suggest that RGS proteins might provide new therapeutic targets to protect the heart from
ischemic injury. We anticipate that this model will be valuable for understanding the time course (chronic versus acute)
and mechanisms of other phenotypic changes that occur following disruption of interactions between Gαi2 and RGS
proteins.
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Background
G protein coupled receptor signaling is mediated by four
major families of G proteins (Gαs, Gαi/o, Gαq, and Gα12).
Gαi coupled receptors play important roles in regulating
inflammation, cardiovascular function, endocrine signa-
ling, drug abuse, and anxiety/depression – related beha-
viors [1-5]. Three different Gαi- isoforms (Gαi1, Gαi2,
Gαi3) have been cloned and characterized. Gαi/o-coupled
responses can be distinguished from responses mediated
by other families of G proteins by their sensitivity to per-
tussis toxin, but the in vivo roles of individual Gαi/o iso-
forms remain obscure.
Signaling through Gαi is suppressed by regulator of G
protein signaling (RGS) proteins which terminate Gαi
signaling by accelerating the hydrolysis of Gα-bound
guanine nucleotide triphosphate (GTP) [6,7]. More than
20 different RGS proteins have been identified. However
identifying the physiological roles of individual RGS pro-
teins through selective pharmacological inhibition is not
yet possible. Knockout mouse models in which indi-
vidual RGS proteins have been genetically deleted have
been useful in identifying the functions of some RGS
proteins, but this approach is complicated by the po-
tential for compensation of the lost RGS protein by
other RGS proteins that may have redundant functions.
Consequently, we have exploited a mutation in Gαi2
(Gαi2
G184S) that blocks RGS binding and activity [8].
This allows us to define the functions of this individual
Gαi-isoform and to explore the physiological roles of in-
teractions between Gαi2 and endogenous RGS proteins
[8,9]. Knock-in mice expressing Gαi2
G184S show enhanced
receptor-dependent signaling through Gαi2 [8,9], and
they exhibit a number of interesting cardiac phenotype
changes including enhanced carbachol-induced brady-
cardia, enhanced isoproterenol-induced cardiac fibrosis,
and premature death in a dilated cardiomyopathy model
[8-12]. Hearts from both homozygous and heterozygous
Gαi2
G184S mutant mice also exhibit smaller infarcts and
better recovery of cardiac contractile function following
an ischemic insult [13]. Genetic disruption of interactions
between Gαi2 and endogenous RGS proteins also pro-
duces several noncardiac phenotypic changes including
antidepressant-like behavior [5], resistance to high fat
diet-induced weight gain, decreased body fat, and protec-
tion from the development of insulin resistance [14].
One limitation of this transgenic model is that the
Gαi2
G184S mutation is chronically expressed throughout
the prenatal and postnatal life of the animal. Thus, it is
unclear whether the phenotypes that have been reported
result from changes during embryological development
and whether the phenotypes require chronic or only acute
disruption of interactions between Gαi2 and endogenous
RGS proteins. In the present study, we addressed this
issue by creating a conditional knock-in mouse model that
conditionally expresses RGS insensitive Gαi2
G184S. This
study focused on the ability of acute Gαi2
G184S expression
to protect the heart from ischemic injury.
Methods
Gene targeting
All protocols and procedures were approved by the
University Committee on Use and Care of Animals at the
University of Michigan and by the Animal Care and Use
Committee of Ohio Northern University. Experimental
procedures and animal husbandry were conducted in
accordance with NIH guidelines. Animals were housed in
a specific pathogen free facility with a 12 hour: 12 hour
light: dark cycle and free access to food and water. Mice
expressing RGS-insensitive Gαi2
G184S were generated by a
“floxed minigene” strategy [15,16]. The targeting construct
to create the conditional knock-in of the G184S mutation
at Gαi2 (Figure 1A) was generated from a 129 BAC library
in a manner similar to that previously described for the
conventional Gαi2
G184S knock-in mutant mice [11]. Ele-
ments included: a 6.4 kb 5’ homology arm containing the
endogenous Gnai2 sequence encompassing exons 2 to 4, a
minigene version of the wild type Gnai2 gene composed
of the fused exons 5 to 8, intron 8 and exon 9 (this Gnai2
wild-type minigene was flanked with loxP sites allowing
its deletion under the action of the Cre recombinase), the
mutated exon 5 containing the G184S mutation (GGGC
to TAGT mutation in position 85 in exon 5), a neo selec-
tion cassette flanked with FRT sites allowing its deletion
under the Flp recombinase action, and a 2.4 kb 3’ ho-
mology arm containing the endogenous Gnai2 sequence
encompassing exons 6 to 9 and sequence located down-
stream of the gene. In addition, AflII and SacI restriction
sites were inserted in the 5’ homology arm at the BstEII
site between Exon 4 and the 5’ loxP site to be used for
Southern blot analysis of the targeted ES cells. A Thymi-
dine Kinase (TK) negative selection marker was inserted
upstream of the 5’ homology arm. ES cells (5 × 106 cells -
SV129 strain) were electroporated (GenOway; Lyon,
France) with 40 μg of linearized plasmid and selection
started 48 hours later with 200 ug/ml of G418 followed by
selection in GANIX to enhance the likelihood of homolo-
gous recombination. Targeted cells were identified by
3’ genomic PCR. Of the 23 positive clones, five also
showed the appropriate presence of the AflII/SacI restric-
tion site on 5’ PCR. All five were confirmed by 5’ and 3’
Southern Blot analysis (13.0 kb EcoNI fragment and 11.5
kb AflII fragment, respectively) (GenOway; Lyon, France).
Mouse generation
Three independent embryonic stem (ES) cell lines with
normal karyotype were used for blastocyst injection into
C57BL/6J host blastocysts. Highly chimeric males were
bred to C57BL/6J female mice and F1 agouti offspring
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mice were genotyped by PCR and Southern blot hybri-
dization to validate germline transmission (GenOway;
Lyon, France). To delete the FRT-flanked neo gene, off-
spring showing the presence of the Gαi2
+/fl-neo-G184S allele
by genomic PCR were crossed against beta-actin FLPe
mice (from the University of Michigan Transgenic Animal
Model Core). Litters from this cross were analyzed for the
presence of the FLP transgene as well as Gαi2 genotypes
by genomic PCR. FLP/Gαi2
+/fl-G184S mice lacking the
neo cassette were backcrossed onto the C57BL/6J strain
to eliminate the FLPe gene. To generate whole-body
Gαi2
G184S conditional knock-in mice, transgenic mice car-
rying the tamoxifen-sensitive, Cre-ERT2 gene driven by
the ROSA26 promoter (The Jackson Laboratory; Bar
Figure 1 Floxed mini-gene targeting strategy for the generation of conditional “knock-in” of Gαi2
*G184S allele. A Exon 5 of the genomic
locus of the gene Gnai2 was replaced by homologous recombination using a vector containing a G184S mutant Exon 5 (E5*) with a 3’ extension
containing Flp Recombinase Target (FRT)-sites (red chevrons) flanking a neo selection cassette and a 5’ extension with Lox P sites (green triangles)
flanking a minigene containing wild-type E5-9. B After introduction of the targeting vector, the neo marker is removed by breeding the Gαi2fl-neo-G184S
positive mice with transgenic Flp recombinase expressing animals. C To generate whole-body Gαi2
*G184S conditional knock-in mice, transgenic mice
carrying tamoxifen-sensitive, Cre-ERT2 gene driven by the Gt(ROSA)26Sortm1 (ROSA) promoter were bred with Gαi2fl/fl-G184S mice. After tamoxifen
administration there is recombination of genomic Lox P sites which leads to removal of the E5-9 minigene and the mutant E5* is positioned in
the normal Gnai2 gene to express the Gαi2*G184S mutant allele. D Southern blot analysis of ES cell genomic DNA following digestion with EcoNI
and hybridization with the 5’-Neo probe to screen for 5’ homologous recombination event. E Southern blot verification analysis of ES cell
genomic DNA following digestion with AflII and hybridization with an external 3’ probe. In figures d and e lanes 1 to 4 are correctly targeted
ES cell clones, lane 5 is a non-targeted (WT) ES cell clone.
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Harbor, ME) were bred with Gαi2
fl-G184S/fl-G184S mice. All
mice used in this study have been backcrossed for five
generations onto the C57BL/6J strain. They were between
8 – 20 weeks old and the number for each experiment is
indicated in the figure legends. Animals were maintained
in a specific pathogen-free facility with a 12-h light/dark
cycle and fed standard laboratory chow and water ad
libitum.
Genotyping
Genomic DNA was isolated from mouse tail using the
HotSHOT method [17] and analyzed in a single PCR reac-
tion using two forward primers A and C (GAGCCCA
TGTTTCTTAAAGAAGCAAGGATA and TCCCACAC
CTTAGTGCCACACCT, respectively) and reverse primer
B (TGAGGACATGCCTTCCCAACACAAT), which amp-
lify the Gαi2
+ (492-bp) and Gαi2
fl-G184S (745-bp) alleles,
respectively.
Tamoxifen preparation and treatment
Tamoxifen (Sigma, T5648) was prepared in peanut oil
(Sigma, P2144) containing 10% ethanol at a concentra-
tion of 60 mg/ml [16]. Daily doses of 50 mg/kg over five
days were given by intraperitoneal injection to induce
recombination. Control mice were treated with vehicle
(90% peanut oil/10% ethanol) alone.
Blood and tissue collection
Blood was withdrawn from the saphenous vein into dipo-
tassium ethylenediamine tetraacetic acid -coated micro-
tubes before the first and 72 hours after the last dose of
tamoxifen and then stored at -80˚C until processing for
analysis. Mice were euthanized by pentobarbital injection
and tissues were quickly removed, snap-frozen in liquid
nitrogen, and stored at -80°C until analysis.
Recombination assessment
Qualitative assessment for recombination, before and
after tamoxifen treatment, was performed by polymerase
chain reaction (PCR) using genomic DNA isolated from
whole blood and tissue samples from genotyped mice
carrying one copy of the ROSA Cre-ERT2 gene and the
indicated Gαi2 alleles (Gαi2
+/+or Gαi2
G184S
) was amplified
by using forward primer A and reverse primer B de-
scribed above. This PCR reaction generates a 659-bp
band only after Cre recombination. PCR reactions for
testing genotype and recombination were carried out
under the following conditions: 95°C for 5 min, 35 cycles
at 95°C, and 64.5°C each for 30 s, followed by extension
at 72°C for 1 min and final extension at 72°C for 2 min.
Western blotting
Tissues were dissected and homogenized in a Bullet
Blender homogenizer (Next Advance; Averill Park, NY)
with RIPA buffer containing protease inhibitors (20 mM
Tris-HCl, pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM
β-glycerophospate, 1% Triton X-100, 0.1% SDS, Com-
plete protease inhibitor cocktail (Roche; Pleasanton, CA).
Protein concentrations were measured using the BCA
Protein Assay kit (Thermo Fisher Scientific; Rockford, IL).
Eighty micrograms of protein were separated on a de-
naturing 12% SDS–PAGE gel and transferred to PVDF
membrane. The membranes were washed, blocked (5%
milk in PBS-T), and incubated in the appropriate anti-
bodies overnight at 4°C. Antibodies for Western blot ana-
lysis: rabbit anti-Gαi2 (a gift from Dr. Susanne Mumby,
University of Texas Southwestern Medical Center) at a
dilution of 1:1000 and mouse anti-GAPDH (Cell Signaling
Technology, Danvers, MA), as loading control, at a dilu-
tion of 1:5000. Secondary antibodies were horseradish per-
oxidase conjugated. Visualization of the protein bands was
done using the Super Signal West Pico chemiluminescent
substrate (Thermo Fisher Scientific, Rockford, IL). Films
were scanned and quantified using Image J software
(NIH, Bethesda, MD). All samples were normalized with
GAPDH as a loading control and the amount of Gαi2 pro-
tein in wild type tissue was set to 100%.
Allele ratio conversion
RNA was isolated from whole blood, heart, brain, and
kidney using a commercial kit (Qiagen, Valencia, CA), and
reverse transcription was carried out using Reverse
Transcription reagents (Applied Biosystems). PCR was
performed using a set of primers that amplify a 442–base
pair segment of Gαi2 cDNA including both wildtype and
Gαi2
G184S. The primers used were CCAGCGTGCGGAT
GATGCC and GATGAGGAGATGAACCGCATGCAT.
The cDNA PCR products obtained for each sample were
purified (Qiagen, Valencia, CA), and directly sequenced
on an ABI 3730XL using the forward primer used for
amplification of Gαi2 in PCR. The allelic expression ratio
of mutant Gαi2
G184S to wildtype Gαi2 in mice was deter-
mined from the chromatogram peak heights of the bases
differentiating between the Gαi2
G184S mutant and wildtype
Gαi2 alleles. Peak heights were determined using Image J
software and mutant allele expression was calculated
using the formula: % mutant allele expression = (T +
A + T-peak heights)/((T + A + T-peak heights) + (G +G +
C-peak heights)) X 100. If any of the peaks of the mutant
or the wild type sequence were not detected in the chro-
matogram the sample was considered 100% wild type or
100% mutant, respectively.
Adult cardiac fibroblast culture
Adult cardiac fibroblasts (ACF) were isolated from mice
as previously described [12,18]. Hearts were quickly iso-
lated, placed in ice-cold perfusion buffer, and then per-
fused via an aortic cannula for 4 min with calcium-free
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perfusion buffer (NaCl, 113 mM; KCl, 4.7 mM; MgSO4-
7H2O, 1.2 mM; Na2HPO4, 0.6 mM; KH2PO4, 0.6 mM;
phenol red, 0.032 mM; HEPES, 10 mM; NaHCO3, 12
mM; KHCO3, 10 mM; taurine, 30 mM; glucose, 5.5
mM; and butanedione monoxime, 10 mM, pH 7.46).
Hearts were then perfused for 8 min with the same buf-
fer containing 0.5 mg/ml collagenase II (Worthington
Biochemicals, Lakewood) and 1.25 μM CaCl2. Hearts
were removed from the apparatus and the ventricles
were suspended in perfusion buffer with collagenase
and 1.25 μM CaCl2. The tissue was disrupted with fine
forceps and by gentle pipetting. Cells were transferred
to buffer containing 1.25 μM CaCl2 and 10% serum to
stop the digestion. Samples were centrifuged at 180×g
for 1 min to remove debris and myocytes. The re-
maining suspended fibroblasts were centrifuged at
300 × g for 10 min, then resuspended in phosphate buf-
fered saline, centrifuged again, the supernatant was dis-
carded, and the final cell pellet was resuspended in
Dulbecco's modified Eagle’s medium supplemented with
1% penicillin/streptomycin, insulin/transferrin/selenium
(ITS from Sigma) 1X, and 10% fetal bovine serum.
cAMP production in adult cardiac fibroblasts
The effect of lysophosphatidic acid (LPA) on 3´,5´ cyclic
adenosine monophosphate (cAMP) production in ACF
was determined in 384-well plates using the Lance Ultra
cAMP kit (PerkinElmer; Waltham, MA). Briefly, ACF
(passage 2) were added at 1,000 cells per well and cAMP
accumulation was initiated by adding stimulation buf-
fer containing 0.5 mM isobutyl-1-methylxanthine and
10 μM forskolin with the indicated concentrations of
LPA. After 30 min at room temperature, the reaction
was stopped by lysing the cells using the buffer supplied
with the PerkinElmer kit. Time-resolved fluorescence
was measured with a Synergy 2 (BioTek; Winooski, VT)
microplate reader.
Langendorff isolated heart preparation and infarct size
measurement
Mice were treated with tamoxifen or vehicle for 5 days as
described above. Fourteen days after the first injection,
mice were anesthetized and heparinized by a single injec-
tion containing pentobarbital (100 mg/kg) and heparin
(150 mg/kg). Hearts were immediately excised and cannu-
lated while bathed in ice-cold Krebs solution. Krebs solu-
tion was perfused through the aortic cannula at a constant
pressure of 75 mmHg. Hearts were subjected to 30 mi-
nutes of ischemia and 2 hours reperfusion as previously
described [13]. Contractile function of the left ventricle
was continuously measured using an intraventricular bal-
loon and infarct size was measured by triphenyltetrazo-
lium chloride staining as described previously [13].
Statistical analyses
Data were analyzed using one-way or two-way analysis
of variance, followed by a Bonferroni’s post test or a
Tukey’s post test when appropriate. GraphPad Prism
version 4.0 (GraphPad Software, San Diego, CA) was
used for statistical analysis.
Results
To implement a conditional knock-in strategy, a replace-
ment-type minigene targeting vector was used to modify
the Gnai2 gene as depicted in Figure 1A-C. This con-
struct was designed to (1) flank an exon 5 through 9
minigene with loxP recombination recognition sites, (2)
insert a neomycin selection cassette that was flanked by
FRT recombination sites downstream of the floxed wild
type Gαi2 coding and regulatory sequences, and (3) re-
place the wildtype genomic exon 5 with the G184S mu-
tant version followed by the remainder of the wildtype
Gαi2 sequence in the normal genomic context. Because
of size constraints on the cloning vector used to create
the targeting construct, exons 5 through 8 were fused
and introns 5-7 were deleted. Intron 8 and non-coding
exon 9 were retained due to the presence of regulatory
elements. The knock-in mutation was introduced into
the genomic exon 5 to change the codon for glycine 184
to serine (Figure 1A). Following electroporation of the
targeting construct into embryonic stem cells, G418-
resistant ES cell clones were screened for gene targeting
by PCR and confirmed by Southern blot analysis. Blots
were hybridized to 5’ and 3’ probes. After genomic DNA
digestion with EcoNI, the 5’ probe hybridized with
a 13.0 kb fragment generated from a recombinant
Gai2
G184S allele (Figure 1D). This was confirmed by blot-
ting with a 3’ probe after genomic DNA digestion with
AflII. This probe hybridized to a 7.9 kb fragment from
the wild type Gai2 allele and an 11.5 kb fragment from a
Gai2
G184S allele (Figure 1E). One ES cell clone was not
targeted (lane 5) and four clones were correctly targeted
(lanes 1 to 4). Three targeted ES cell clones with normal
karyotype were used to produce germline-competent
chimeric mice using standard techniques. After FLP re-
combinase crosses, mice that were heterozygous for
the targeted locus without the neomycin cassette (fl-G184S
allele) were subsequently backcrossed with C57BL/6J
mice to eliminate the beta-actin FLP transgene. Figure 2A
shows representative results from the PCR screening used
to select mice with the desired genotype.
To demonstrate a global, time-dependent, and Cre-
mediated conversion of the conditional allele (fl-G184S) to
the RGS insensitive allele (G184S), we crossed mice that were
homozygous for the fl-G184S allele (Gαi2
fl-G184S/fl-G184S)
mice with a tamoxifen-dependent Cre general deleter
mouse line [19-21]. This line expresses a tamoxi-
fen-sensitive Cre (Cre-ERT2) from the ROSA26 locus
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(Figure 1C). When tamoxifen is administered, its meta-
bolite 4-OH tamoxifen binds to the Cre-ERT2 which trans-
locates to the nucleus facilitating recombination of
genomic loxP sites. As shown in Figure 2B, this removes
the E5-9 minigene and positions mutant Exon 5 (E5*) in
the normal Gnai2 genomic context to express the mu-
tant Gαi2
G184S protein. Gαi2
fl-G184S/fl-G184S and Cre-
ERT2/Gαi2
fl-G184S/fl-G184S mice are viable and do not
show any gross developmental abnormalities.
Reverse transcription-polymerase chain reaction (RT-
PCR) analysis was used to amplify a 442-bp cDNA pro-
duct expressed from the Gnai2 gene to assess the ratio
of mutant to wildtype Gαi2 RNA expression. Only the
Cre-ERT2/Gαi2
+/fl-G184S, or Cre-ERT2/Gαi2
fl-G184S/fl-G184S
mice express mutant mRNA after tamoxifen treatment.
Gαi2-specific PCR products from each genotype were se-
quenced (Figure 3A). This analysis confirmed that the
Gαi2 cDNA sequence from Gαi2
fl-G184S/fl-G184S mice prior
to tamoxifen treatment was identical to the previously
published mouse cDNA sequence [22,23]. In contrast, the
Gαi2 cDNA sequence from Cre-ER
T2/Gαi2
+/fl-G184S, or
Cre-ERT2/Gαi2
fl-G184S/fl-G184S mice revealed the nucleotide
changes that were introduced to change the codon for gly-
cine at 184 to serine. Peak heights from the chromato-
grams were used to quantify the relative amount of
mutant mRNA expression in several tissues [24]. In mice
that were homozygous for fl-G184S (Gαi2
fl-G184S/fl-G184S),
we found 60 – 100% conversion to the mutant sequence
in most tissues evaluated (Figure 3B). As expected,
heterozygous animals (Gαi2
+/fl-G184S) exhibited lower
rates of conversion because they retained one copy of
the wildtype allele. The lack of conversion in brain
was presumably due to lack of Cre-ERT2 expression in
post-mitotic neurons, and low brain penetration by
tamoxifen [20].
Surprisingly, Gαi2 protein expression levels were signifi-
cantly reduced in several organs (heart, brain, and kidney)
isolated from Gαi2
fl-G184S/fl-G184S and Cre-ERT2/Gαi2
fl-G184S/
fl-G184S mice compared to Gαi2
+/+control animals that do
not express Cre or the Gαi2
G184S mutation (Figure 4). We
also assessed whether there were compensatory changes in
other G proteins in heart ventricles. We found no de-
tectable levels of Gαo, Gαi1, or Gαi3 in wildtype ventricles
nor were they present in Gαi2
fl-G184S/fl-G184S or Cre-ERT2/
Figure 2 Representative agarose gel images assessing genotypes and recombination in mice. A PCR genotyping was done simultaneously
using three primers A, B, and C from Figure 1. A 492-bp band represents the wild-type Gnai2 allele and the 745-bp band represents the Gnai2 fl-G184S
conditional allele after removal of the neo cassette. B Genomic DNA extracted from blood was amplified before and after tamoxifen treatment. Lanes
1 and 2 were from Cre negative Gα fl-G184S/fl-G184S mice while lanes 3-6 were from Cre-ERT2, Gαi2fl-G184S/fl-G184S mice. Tamoxifen-induced recombination
was evaluated using primers A and B and confirms the in vivo conversion to the *G184S allele for expression of the RGS-insensitive Gαi2. The 659-bp
band was exclusively generated after tamoxifen treatment (Tam). The non-recombined fl-G184S allele is not detected due to the large size of the PCR
product (3189-bp).
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Gαi2
fl-G184S/fl-G184S ventricles either before or after tamoxi-
fen treatment (data not shown). This is consistent with
previous reports that Gαi2 is a predominant Gαi isoform in
the myocardium [25,26].
We previously demonstrated that embryonic fibroblasts
from conventional (i.e. non-conditional) Gαi2
G184S knock-
in mice have enhanced activity in several biochemical and
physiological measures of the Gαi signaling pathway [8].
Thus, we investigated the functional consequences of con-
ditional Gαi2
G184S expression at the cellular level in a
cAMP inhibition assay. Adult cardiac fibroblasts from
mice treated with tamoxifen (which developed ~90% mu-
tant allele expression, data not shown) were isolated and
cultured. cAMP production in these cells was measured
following exposure to forskolin (10 μM) and increasing
concentrations of lysophosphatidic acid (LPA). Data were
compared by two-way ANOVA with genotype and LPA
concentration as variables. A significant effect of genotype
(P < 0.05) in the inhibition of cAMP production was ob-
served. Bonferroni’s post test revealed that ACF from the
conditional knock-in mice (Cre-ERT2/Gαi2) had signifi-
cantly (P < 0.05) augmented inhibition of cAMP produc-
tion with the highest concentration of LPA compared to
cells from Gαi2
fl-G184S/fl-G184S mice that do not convert to
the G184S mutation (Figure 5). These data are consistent
with our previous finding that LPA-induced inhibition of
adenylate cyclase activity is enhanced in embryonic fibro-
blasts in the nonconditional Gαi2
G184S model [13], and
they provide evidence that agonist-induced Gαi2 signaling
is enhanced in cardiac fibroblasts that conditionally ex-
press the Gαi2
G184S allele.
We previously demonstrated that the conventional
Gαi2
G184S mutant mice (both heterozygotes and homozy-
gotes) are resistant to ischemia-reperfusion injury [13].
However, it was unclear whether this phenotype resulted
from Gαi2
G184S expression during embryonic development
or whether the cardioprotective phenotype requires
chronic or acute Gαi2
G184S expression. In the present
study, we found that ischemia-induced infarct size was
significantly decreased in tamoxifen-treated Cre-ERT2/
Gαi2
fl-G184S/fl-G184S compared to both vehicle-treated Cre-
ERT2/Gαi2
fl-G184S/fl-G184S hearts and tamoxifen-treated
Gαi2
fl-G184S/fl-G184S without Cre expression (Figure 6).
Consistent with reduced myocardial infarct size (Figure 6),
hearts isolated from tamoxifen-treated Cre-ERT2/Gαi2
fl-
G184S/fl-G184S exhibited significantly enhanced postischemic
recovery of developed pressure compared to hearts iso-
lated from either vehicle-treated Cre-ERT2/Gαi2
fl-G184S/
fl-G184S mice or tamoxifen-treated Gαi2
fl-G184S/fl-G184S mice
that do not express Cre-ERT2 (Table 1). Postischemic
recovery of + dP/dT and –dP/dT were also enhanced
in hearts isolated from tamoxifen treated Cre-ERT2/
Gαi2
fl-G184S/fl-G184S animals. Postischemic recovery of end
diastolic pressure was nominally lower in tamoxifen-
treated Cre-ERT2/Gαi2
fl-G184S/fl-G184S compared to the
other groups (Table 1). However, this did not reach statis-
tical significance. These data are consistent with our pre-
vious report that nonconditional expression of Gαi2
G184S
protects the heart from ischemic injury [13]. Importantly,
they extend our previous findings by demonstrating that
the cardioprotective phenotype does not result from em-
bryonic or chronic expression of Gαi2
G184S. Rather, acute
Figure 3 Efficiency and genotype specificity of Cre-induced mutant allele mRNA conversion (MAC) in tissues after tamoxifen treatment
in Gαi2
fl-G184S mice. A Representative chromatograms of sequenced PCR products from mRNA purified from hearts of tamoxifen-treated mice (50
mg/kg i.p. on five consecutive days). Mice lacking Cre (Cre-ERT2-) showed no evidence of the TAGT sequence expected for G184S mutant mRNA
(top chromatogram). For mice expressing Cre (Cre-ERT2+), the percentage conversion to the mutated sequence (% MAC) was higher in mice that
were homozygous for the G184S mutation (Gαi2fl-G184S/fl-G184S, lower chromatogram) than in heterozygous (Gαi2+/fl-G184S, middle chromatogram)
animals. B The extent of recombination was higher in blood and liver than in other tissues with heart showing approximately 80% MAC in homozygotes.
Values are expressed as the mean (±SE, n = 3) of the percentage of the mutated allele determined from the added peak heights of the three changed
bases (see Methods).
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disruption of interactions between Gαi2 and endogenous
RGS proteins is sufficient to induce cardioprotection.
Discussion
We previously described a mouse model in which sig-
naling by Gαi2 was enhanced by introduction of a point
mutation (G184S) that blocks negative regulation by RGS
proteins [8]. These mice exhibited a number of complex
and interesting phenotypes including protection from
cardiac ischemia/reperfusion injury [13]. However, it was
unclear whether this cardioprotective phenotype resul-
ted from changes in Gαi2 signaling during embryonic
Figure 4 Gαi2 protein expression is reduced in mice conditionally expressing Gαi2
G184S. Gαi2 protein expression was measured by Western
blot in hearts (A), brains (B), and kidneys (C) isolated from mice treated with tamoxifen (50 mg/kg; shaded bars) or vehicle (nonshaded bars) for
5 consecutive days. The membrane was stripped and reblotted with a GAPDH antibody as a loading control. Values represent the mean ± SE of
tissues from three different animals for each genotype. Data are normalized to Gαi2 protein expression in tissues from wildtype C57B/6J mice that
do not express Cre and do not carry the Gαi2G184S mutation. Panel D shows a representative blot of kidneys from three different animals of each
genotype. * and ** indicate significant differences (p < 0.05 and p < 0.01, respectively) relative to control mice (Gαi2
+/+) that do not carry the Cre-ERT2 or
Gαi2
fl-G184S/fl-G184S genes.
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development. It was also unknown whether chronic
Gαi2
G184S expression was required or whether acute ex-
pression was sufficient to protect the heart from ischemic
injury. These are important issues because the potential
finding that embryonic or chronic expression of Gαi2
G184S
is required for cardioprotection would likely preclude the
use of pharmacological RGS inhibitors from therapeutic
use in the treatment of ischemic heart disease. The
present study extends our previous findings by demon-
strating that acute (days rather than months) disruption of
interactions between Gαi2 and endogenous RGS proteins
is sufficient to protect the heart from ischemic injury.
These data suggest that RGS proteins might provide novel
therapeutic targets to protect the heart from ischemic
injury.
Conditional expression of Gαi2
G184S resulted in a 55%
reduction in infarct size relative to hearts isolated from
tamoxifen-treated mice that did not express Cre-ERT2,
and a 65% reduction in infarct size compared to hearts
isolated from mice that expressed Cre-ERT2 but were not
treated with tamoxifen. By comparison, we previously
reported that nonconditional expression of Gαi2
G184S re-
sulted in 41% and 68% reductions in infarct sizes in hearts
isolated from mice that were heterozygous or homozygous
for the Gαi2
G184S mutation, respectively [13]. Recovery of
developed pressure, +dP/dT, and -dP/dT were signifi-
cantly increased in both models of Gαi2
G184S expression
(Table 1 and [13]). Thus, conditional expression of this
mutation produced a cardioprotective phenotype that was
similar to the phenotype previously observed in the con-
ventional (nonconditional) Gαi2
G184S knockin model.
Mice expressing the Gαi2
G184S in a nonconditional
fashion also exhibit several noncardiac phenotypic differ-
ences including: resistance to high fat diet-induced
weight gain and resistance to the development of insulin
insensitivity, reduced embryonic viability, elevated neu-
trophil counts, and antidepressant-like behavior [5,8,14].
We anticipate that the conditional Gαi2
G184S expression
model described here will be helpful in characterizing
the temporal requirements (acute versus chronic) of
Gαi2
G184S expression for some of these phenotypes. Our
finding that tamoxifen produced very little conversion to
the Gαi2
G184S mutation in the brain suggests that this
model may not be useful for characterizing the anxiolytic
or antidepressant-like behavior that has been previously
reported in nonconditional Gαi2
G184S mice [5]. On one
hand, this represents a significant limitation of this
model. However, the observation that the conventional
Gαi2
G184S model, but not the conditional Gαi2
G184S
model, expresses the G184S mutation in the brain might
be useful for elucidating the ability of enhanced Gαi2
signaling in the central nervous system to impact the
function of peripheral tissues. The reason for a lack of
conversion to the Gαi2
G184S mutation in the brain is un-
clear. However, other investigators using the Cre-ERT2
system have reported similar results. Seibler et al. con-
firmed that Cre-ERT2 is expressed in the brain and sug-
gested that the lack of recombination may reflect low
local concentrations of 4-hydroxytamoxifen [27].
The tamoxifen- and Cre-dependent recombination
and expression of mutant mRNA meets the criteria
planned for the engineered Gnai2 locus: lack of mutant
mRNA expression before tamoxifen treatment with good
conversion to the G184S mutation after tamoxifen treat-
ment. We did observe reduced Gαi2 protein expression
in the heart, kidney, and brain of Gαi2
flG184S/fl-G184S and
Cre-ERT2/Gαi2
flG184S/fl-G184S mice relative to wildtype
mice that do not express Cre or carry the G184S muta-
tion, suggesting that the loss of introns in the minigene
that carries the wildtype sequence and/or the residual
LoxP or FLP recombinase (FRT) sites may perturb regu-
latory and/or splicing elements. However, the observa-
tion that LPA-induced inhibition of cAMP production is
augmented in cardiac fibroblasts isolated from Cre-
ERT2/Gαi2
flG184S/fl-G184S mice (Figure 5) indicates that
Figure 5 Enhanced inhibition of forskolin-stimulated adenylate
cyclase by lysophosphatidic acid following conditional induction
of the Gαi2
G184S mutation in adult cardiac fibroblasts.
Concentration-response curves were generated from adult cardiac
fibroblasts isolated from three different mice of each genotype after
treatment with tamoxifen (50 mg/kg i.p. on five consecutive days). Data
from 5 independent determinations for both Gαi2fl-G184S/fl-G184S and
Cre-ERT2/Gαi2*G184S/*G184S are shown as mean ± SE. Data are normalized
to cAMP production in the presence of 10−13 M lysophosphatidic acid.
Two way ANOVA revealed a significant effect for genotype [F = 5.58 (1,8)
p < 0.05] and a significant effect for lysophosphatidic acid concentration
[F = 12.09 (8, 64) p < 0.0001]. * indicates a significant difference (p < 0.05
compared to Gαi2fl-G184S/fl-G184S cells treated with 10−6M LPA) using
Bonferroni’s post test.
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Figure 6 Conditional expression of Gαi2
G184Sprotects the heart from ischemic injury. Conditional expression of Gαi2G184S significantly (p < 0.001)
decreased infarct sizes in hearts exposed to 30 min of ischemia (A). Values represent means ± SE. The number of replicates for each group is shown
within the bars. Data were compared by one way ANOVA and posthoc Tukey analysis. *** indicates a significant difference (p < 0.001) compared to
hearts isolated from tamoxifen treated Gαi2 fl-G184S/fl-G184S mice, and ### indicates a significant difference (p < 0.001) compared to hearts isolated
from Cre-ERT2/Gαi2 fl-G184S/fl-G184S mice that were treated with vehicle instead of tamoxifen. Photographs of representative triphenyltetrazolium
chloride-stained hearts are shown in panel B.
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Table 1 Preischemic and postischemic recovery of contractile function
Preischemic Postischemic recovery
Gαi2
fl-G184S/fl-G184S +
tamoxifen (n = 6)
Cre-ERT2/Gαi2
fl-G184S/fl-G184S +
tamoxifen (n = 6)
Cre-ERT2/Gαi2
fl-G184S/
fl-G184S+ vehicle (n = 4)
Gαi2
fl-G184S/fl-G184S +
tamoxifen (n = 6)
Cre-ERT2/Gαi2/
fl-G184S/fl-G184S +
tamoxifen (n = 6)
Cre-ERT2/Gαi2
fl-G184S/fl-G184S +
vehicle (n = 4)
Developed pressure
(mmHg)
130 ± 6 140 ± 8 132 ± 6 45 ± 5 78 ± 8 * # 29 ± 7
+dP/dT (mmHg/sec) 6375 ± 570 6145 ± 621 4587 ± 251 2223 ± 321 3557 ± 521 # 985 ± 258
-dP/dT (mmHg/sec) -4471 ± 291 -4601 ± 275 -3837 ± 235 -1600 ± 197 -2581 ± 263 * # -908 ± 243
End diastolic pressure
(mmHg)
5.7 ± 1.0 6.2 ± 0.9 5.0 ± 1.0 30 ± 2 21 ± 3 33 ± 7
Coronary flow rate
(ml/min)
4.5 ± 0.4 4.1 ± 0.3 4.6 ± 0.4 2.7 ± 0.3 2.6 ± 0.2 2.9 ± 0.4
Preischemic contractile function was measured prior to 30 minutes of ischemia. Postischemic recovery of contractile function was measured following 1 hour of reperfusion. Data from each group were compared by one way
ANOVA and posthoc Tukey analysis (preischemic and postischemic values were analyzed separately from one another). There were no significant differences between groups for any parameters of preischemic contractile
function. *indicates a significant difference (p < 0.05) in postischemic recovery of contractile function compared to hearts isolated from tamoxifen treated Gαi2
fl-G184S/fl-G184S mice. # indicates a significant difference (p < 0.01) in
postischemic recovery of contractile function compared to hearts isolated from Cre-ERT2/Gαi2
fl-G184S/fl-G184S mice that were treated with vehicle instead of tamoxifen.
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agonist-induced signaling via Gαi2 is actually increased
(relative to fibroblasts that do not express the mutation),
despite decreased Gαi2 expression levels. This presum-
ably occurs because the negative regulatory effect of
RGS proteins toward Gαi2 is disrupted in these cells.
Many different Gαi-coupled receptors are known to pro-
tect the heart from ischemia/reperfusion injury. Thus,
the finding that conditional expression of Gαi2
G184S pro-
duces a cardioprotective phenotype is also consistent
with enhanced Gαi2 signaling despite decreased Gαi2
protein expression.
Conclusions
In conclusion, the conditional Gαi2
G184S knock-in model
described here permits the disruption of interactions
between Gαi2 and endogenous RGS proteins in a time-
dependent manner. Our data demonstrate that acute
(rather than chronic) disruption of interactions between
RGS proteins and Gαi2 is sufficient to protect the heart
from ischemic injury. This suggests that the develop-
ment of chemical inhibitors of RGS proteins or other
agents that disrupt interactions between RGS proteins
and Gαi2 might provide new therapeutic tools to protect
the heart from ischemic injury. In addition, we anticipate
that this transgenic mouse model will provide a valuable
tool for characterizing the mechanisms by which disrup-
tion of RGS protein-Gαi2 interactions confers other phe-
notypes that have been identified in mice expressing
Gαi2
G184S.
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